On June 24, 2022 TOLREMO therapeutics AG reported that Dr. Karl Schumacher, MD, MHBA, has joined the company as Chief Medical Officer (CMO). Dr. Schumacher will lead the clinical and medical programs of TOLREMO in support of the company’s lead asset TT125-802, that is expected to enter the clinic in early 2023 (Press release, TOLREMO, JUN 24, 2022, View Source [SID1234616248]). He will help in the further advancement of TOLREMO’s platform, addressing the unmet medical need of non-genetic cancer drug resistance.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
«We are delighted to have Karl join TOLREMO’s executive management team in this exciting phase for the company. With more than 10 years of clinical development experience in oncology focusing on combination therapies and drug resistance, he will add tremendous value to our drug development programs» said Dr. Stefanie Flückiger-Mangual, CEO and co-founder of TOLREMO.
DOWNLOAD THE FULL PRESS RELEASE
Dr. Schumacher practiced surgical oncology for several years before joining the life sciences industry. Prior to joining TOLREMO, he held various roles in the pharmaceutical industry focusing on drug combinations to prevent resistance to targeted therapies in multiple cancer types. He has been instrumental to the clinical development of targeted and innovative anti-cancer therapies for NSCLC, breast cancer and melanoma. He joins TOLREMO from Merck KGaA where he was Vice President Clinical Development for the MET inhibitor tepotinib (Tepmetkoâ) and the DNA damage response (DDR) inhibitor portfolio.
«I am excited to join TOLREMO at this pivotal phase of the company’s development. I am looking forward to applying my clinical expertise with drug combinations and cancer drug resistance to the company’s clinical development. I am convinced that TT125-802 has a high potential to be developed as a versatile combination partner to a number of targeted therapies» said Dr. Karl Schumacher.